PROGNOSTIC VALUE OF SIRTUIN-1 LEVEL IN BLOOD SERUM OF PATIENTS WITH CHRONIC CORONARY SYNDROME, CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THEIR COMBINATION

Abstract

The aim of the work – to compare the levels of serum sirtuin-1 SIRT1 in patients withCOPD and CCS in their isolated and combined course.Materials and methods. 60 patients diagnosed with COPD, CCS and combined courseof COPD with CCS, as well as 10 practically healthy individuals as a control group,participated in the study. The degree of severity of COPD was assessed by the frequencyof exacerbations and indicators of external respiratory function (ERF): the ratio ofFEV1 (forced expiratory volume in the first second) to FVLC (forced vital capacity of thelungs), as well as the values of FEV1 and VLC. A questionnaire was used to assess theseverity of symptoms, which included the mMRC (modified Medical Research Council),dyspnea severity scale and the COPD Assessment Test. The serum level of SIRT1 wasinvestigated by enzyme-linked immunosorbent assay using Human SIRT1 ELISAKitreagents. Statistical processing of the results was carried out using Microsoft Excel andStatistica 10.0 software.The results. A study that included measuring the level of SIRT1 in blood serum showedthe following results: in patients with COPD, the average level of SIRT1 was 5.21±1.16ng/ml, in patients with C it was 6.58±1.40 ng/ml, in patients with a combined course ofCOPD and CCS – 2.32±0.73 ng/ml. The level of SIRT1 in these groups was significantlylower compared to the control group, in which it was 12.23±1.59 ng/ml (p=0.01).
 Conclusions. In patients with COPD, CCS, or a combination of these diseases, thelevel of SIRT1 in the blood is lower compared to the control group. Close correlationsbetween the level of SIRT1 in the blood and impaired external respiration, age, symptoms(measured by the mMRC scale and the CAT assessment test), and the severity of thecourse of the disease in patients with COPD and CCS, were revealed.